Cetera Investment Advisers Eli Lilly & CO Transaction History

Cetera Investment Advisers

$44.2 Billion
Q3 2024

A detailed history of Cetera Investment Advisers transactions in Eli Lilly & CO stock. As of the latest transaction made, Cetera Investment Advisers holds 226,792 shares of LLY stock, worth $171 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

226,792

Previous 224,922 0.83%

Holding current value

$171 Million

Previous $204 Million 1.33%

% of portfolio

0.45%

Previous 0.48%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$772.14 - $960.02 $1.44 Million - $1.8 Million	1,870 Added 0.83%	226,792 $201 Million
Q2 2024 Aug 22, 2024	SELL	$724.87 - $909.04 $287,773 - $360,888	-397 Reduced 0.18%	224,922 $204 Million
Q1 2024 May 24, 2024	BUY	$592.2 - $792.28 $110 Million - $147 Million	185,814 Added 470.36%	225,319 $175 Million
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $19.8 Million - $26.5 Million	-33,495 Reduced 45.88%	39,505 $30.7 Million
Q4 2023 Feb 13, 2024	BUY	$525.19 - $619.13 $630,753 - $743,575	1,201 Added 1.67%	73,000 $42.6 Million
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $1.77 Million - $2.44 Million	4,069 Added 6.01%	71,799 $38.6 Million
Q2 2023 Aug 09, 2023	BUY	$350.74 - $468.98 $1.71 Million - $2.28 Million	4,865 Added 7.74%	67,730 $31.8 Million
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $141,336 - $165,993	455 Added 0.73%	62,865 $21.6 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $5.65 Million - $6.58 Million	17,566 Added 39.17%	62,410 $22.8 Million
Q3 2022 Nov 10, 2022	SELL	$296.48 - $337.87 $2.47 Million - $2.81 Million	-8,330 Reduced 15.67%	44,844 $14.5 Million
Q2 2022 Aug 11, 2022	BUY	$278.73 - $327.27 $1.57 Million - $1.84 Million	5,616 Added 11.81%	53,174 $17.2 Million
Q1 2022 May 13, 2022	BUY	$234.69 - $291.66 $231,639 - $287,868	987 Added 2.12%	47,558 $13.6 Million
Q4 2021 Feb 14, 2022	SELL	$224.85 - $279.04 $624,633 - $775,173	-2,778 Reduced 5.63%	46,571 $12.9 Million
Q3 2021 Nov 16, 2021	SELL	$221.6 - $272.71 $1.25 Million - $1.53 Million	-5,625 Reduced 10.23%	49,349 $11.4 Million
Q2 2021 Aug 13, 2021	BUY	$180.55 - $233.54 $1.4 Million - $1.81 Million	7,752 Added 16.42%	54,974 $12.6 Million
Q1 2021 May 17, 2021	SELL	$164.32 - $212.72 $77,559 - $100,403	-472 Reduced 0.99%	47,222 $8.82 Million
Q4 2020 Feb 17, 2021	BUY	$130.46 - $172.63 $5.25 Million - $6.94 Million	40,218 Added 537.96%	47,694 $8.05 Million
Q3 2020 Nov 13, 2020	BUY	$146.22 - $169.13 $90,363 - $104,522	618 Added 9.01%	7,476 $1.11 Million
Q2 2020 Aug 13, 2020	SELL	$136.42 - $164.18 $26,329 - $31,686	-193 Reduced 2.74%	6,858 $1.13 Million
Q1 2020 May 08, 2020	BUY	$119.05 - $147.35 $198,337 - $245,485	1,666 Added 30.94%	7,051 $978,000
Q4 2019 Feb 10, 2020	SELL	$106.92 - $132.43 $56,346 - $69,790	-527 Reduced 8.91%	5,385 $704,000
Q3 2019 Nov 06, 2019	SELL	$106.79 - $116.16 $16,872 - $18,353	-158 Reduced 2.6%	5,912 $661,000
Q2 2019 Aug 12, 2019	SELL	$110.79 - $129.32 $120,650 - $140,829	-1,089 Reduced 15.21%	6,070 $674,000
Q1 2019 May 06, 2019	BUY	$111.31 - $131.02 $8,682 - $10,219	78 Added 1.1%	7,159 $927,000
Q4 2018 Feb 15, 2019	SELL	$105.9 - $118.64 $16,202 - $18,151	-153 Reduced 2.12%	7,081 $823,000
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $66,970 - $83,701	780 Added 12.09%	7,234 $781,000
Q2 2018 Aug 14, 2018	BUY	$75.7 - $86.88 $43,451 - $49,869	574 Added 9.76%	6,454 $554,000
Q1 2018 May 09, 2018	SELL	$74.21 - $87.6 $397,988 - $469,798	-5,363 Reduced 47.7%	5,880 $455,000
Q4 2017 Feb 08, 2018	BUY	$81.94 - $87.89 $67,026 - $71,894	818 Added 7.85%	11,243 $944,000
Q3 2017 Nov 16, 2017	SELL	$77.07 - $85.54 $28,207 - $31,307	-366 Reduced 3.39%	10,425 $894,000
Q2 2017 Aug 17, 2017	SELL	N/A	-1,015 Reduced 8.6%	10,791 $886,000
Q2 2017 Aug 14, 2017	BUY	N/A	11,806	11,806 $967,000

Others Institutions Holding LLY

# of Institutions

4,003

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $716B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.

Account

Cetera Investment Advisers Eli Lilly & CO Transaction History